Nerve Growth Factor in Rheumatic Diseases

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 2, 2010, Pages 109-126

  Seidel, Matthias F ^a   Herguijuela, Marjeta ^b   Forkert, Randolf ^c   Otten, Uwe ^d  

^a Medizinische Klinik und Poliklink I Rheumatology   (Germany)

^b Seidel Klinik   (Germany)

^c Johanniter Krankenhaus   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Nerve growth factor; Neurogenic inflammation; Review; Rheumatic diseases

Indexed keywords

ANTINOCICEPTIVE AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; PLACEBO; PROTEIN TYROSINE KINASE A; RECOMBINANT NERVE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ANTIBODY TITER; BEHCET DISEASE; CHRONIC PAIN; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TISSUE LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FIBROMYALGIA; GENE ACTIVATION; HUMAN; HYPERALGESIA; IMMUNOMODULATION; INFLAMMATION; INTERVERTEBRAL DISK HERNIA; JUVENILE RHEUMATOID ARTHRITIS; KNEE OSTEOARTHRITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NERVE ROOT COMPRESSION; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPINAL CORD COMPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TEMPORAL ARTERITIS; UPREGULATION; VERTEBRAL CANAL STENOSIS;

ANIMALS; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; MEDLINE; NERVE GROWTH FACTOR; RECOMBINANT PROTEINS; RHEUMATIC DISEASES; SYNOVIAL FLUID;

EID: 77957019647     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.03.002     Document Type: Review

References (227)

1. Kidd B.L., Mapp P.I., Gibson S.L., Polak J.M., O'Higgins F., Buckland-Wrigth J.C., et al. A neurogenic mechanism for symmetrical arthritis. Lancet 1989, 2(8672):1128-1130.
2. Pezet S., McMahon S.B. Neurotrophins: mediators and modulators of pain. Ann Rev Neurosci 2006, 29:507-538.
3. Thompson M., Bywaters E.G.L. Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis 1962, 21:370-377.
4. Seidel M., Tsalik J., Vetter H., Müller W. Substance P in rheumatic disease. Curr Rheum Rev 2007, 1(3):17-30.
5. Klein R. Role of neurotrophins in mouse neuronal devolopment. FASEB J 1994, 8(10):738-744.
6. Amann R., Sirinathsinghji D.J.S., Donnerer J., Lieberman I., Schuligoi R. Stimulation by nerve growth factor of neuropeptide synthesis in the adult rat in vivo: bilateral response to unilateral intraplantar injections. Neurosci Lett 1996, 203:171-174.
7. Lindsay R.M., Harmer A.J. Nerve growth factor regulates expression of neuropeptides genes in adult sensory neurons. Nature 1989, 337:362-364.
8. Aloe L., Bracci-Laudiero L., Bonini S., Manni L. The expanding role of nerve growth factor: from the neurotrophic activity to immunological diseases. Allergy 1997, 52(9):883-894.
9. Leibrock J., Lottspeich F., Hohn A., Hofer M., Hengerer B., Masiakowski P., et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989, 341(6238):149-152.
10. Ernfors P., Ibáñez C.F., Ebendal T., Olson L., Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarity to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA 1990, 87(14):5454-5458.
11. Maisonpierre P.C., Belluscio L., Squinto S., Ip N.Y., Furth M.E., Lindsay R.M., et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990, 247(4949 Pt. 1):1446-1451.
12. Berkemeier L.R., Winslow J.W., Kaplan D.R., Nikolics K., Goeddel D.V., Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 1991, 7(5):857-866.
13. Hallbook F., Ibanez C.F., Persson H. Evolutionary studies of nerve growth factor family reveal a new member abundantly expressed in Xenopus ovary. Neuron 1991, 6:845-858.
14. Götz R., Köster R., Winkler C., Raulf F., Lottspeich F., Schartl M., et al. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994, 372(6503):266-269.
15. Jelsma J.N., Aguayo A.J. Trophic factors. Curr Opinion Neurobiol 1994, 4(5):717-725.
16. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci 1993, 13(7):2739-2748.
17. Lindsay R.M., Wiegand S.J., Altar C.A., DiStefano P.S. Neurotrophic factors: from molecule to man. Trends Neurosci 1994, 17(5):182-190.
18. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Ann Rev Neurosc 2001, 24:1217-1281.
19. Adler R., Landa K.B., Manthorpe M., Varon S. Cholinergic neuronotrophic factors: intraocular distribution of trophic activity for ciliary neurons. Science 1979, 204:1434-1436.
20. Yamamori T., Fukada K., Aebersold R., Korsching S., Fann M.J., Patterson P.H. The cholinergic neuronal differentiation factor from heart cells is identical to leukemia inhibitory factor. Science 1989, 246(4936):1412-1416.
21. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
22. Varon S., Nomura J., Shooter E.M. Reversible dissociation of the mouse nerve growth factor protein into different subunits. Biochem 1968, 7:1296-1303.
23. Bresnahan P.A., Leduc R., Thomas L., Thorner J., Gibson H.L., Brake A.J., et al. Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-β-NGF in vivo. J Cell Biol 1990, 111:2851-2859.
24. Dicou E., Lee J., Brachet P. Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat. Proc Natl Acad Sci USA 1986, 83:7084-7088.
25. Arnett M.G., Ryals J.M., Wright D.E. pro-NGF, sortilin, and p75(NTR): potential mediators of injury-induced apoptosis in the mouse dorsal root ganglion. Brain Res 2007, 1183:32-42.
26. Lakshmanan J., Burns C., Smith R.A. Molecular forms of nerve growth factor in mouse submaxillary glands. Biochem Biophys Res Commun 1988, 152(3):1008-1014.
27. Reinshagen M., Geerling I., Eysselein V.E., Adler G., Huff K.R., Moore G.P., et al. Commercial recombinant human beta-nerve growth factor and adult rat dorsal root ganglia contain an identical molecular species of nerve growth factor prohormone. J Neurochem 2000, 74(5):2127-2133.
28. Yiangou Y., Facer P., Sinicropi D.V., Boucher T.J., Bennett D.L., McMahon S.B., et al. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. JPNS 2002, 7(3):190-197.
29. Darling T.L.J., Petrides P.E., Beguin P., Frey P., Shooter E.M., Selby M., et al. The biosynthesis and processing of proteins in the mouse 7S nerve growth factor complex. Cold Spring Harbor Symp Quant Biol 1983, 48(Pt. 1):427-434.
30. Selby M.J., Edwards R., Sharp F., Rutter W.J. Mouse nerve growth factor gene: structur and expression. Mol Cell Biol 1987, 7(9):3057-3064.
31. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001, 18(2):210-220.
32. Server A.C., Shooter E.M. Nerve growth factor. Adv Protein Chem 1977, 31:339-409.
33. Ullrich A., Gray A., Berman C., Dull T.J. Human β-nerve growth factor gene sequence highly homologous to that of mouse. Nature 1983, 303:821-825.
34. Scott J., Selby M., Urdea M., Quiroga M., Bell G.I., Rutter W.J. Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor. Nature 1983, 302(5908):538-540.
35. Varon S., Shooter E.M. The nerve growth factor proteins of the mouse submaxillary gland. Biochemistry of brain and behaviour 1970, 41-64. Plenum, New York, NY. R.E. Bowman, S.P. Datta (Eds.).
36. Greene L.A., Shooter E.M., Varon S. Subunit interaction and enzymatic activity of mouse 7S nerve growth factor. Biochemistry 1969, 8(9):3735-3741.
37. Evans B.A., Richards R.I. Genes for the α and γ subunits of mouse nerve growth factor are contiguous. EMBO J 1985, 4(1):133-138.
38. Thomas K.A., Baglan N.C., Bradshaw R.A. The amino acid sequence of the γ-subunit of mouse submaxillary gland 7S nerve growth factor. J Biol Chem 1981, 256(17):9156-9166.
39. Ullrich A., Gray A., Wood W.I., Hayflick J., Seeburg P. Isolation of a cDNA clone coding for the gamma-subunit of mouse nerve growth factor using a high-stringency selection procedure. DNA 1984, 3(5):387-392.
40. Isackson P.J., Brandshaw R.A. The α-subunit of mouse 7S nerve growth factor is an inactive serine protease. J Biol Chem 1984, 259(9):5380-5383.
41. Thomas K.A., Silverman R.E., Jeng I., Baglan N.C., Bradshaw R.A. Electrophoretic heterogeneity and polypeptide chain structure of the γ-subunit of mouse submaxillary 7S nerve growth factor. J Biol Chem 1981, 256(17):9147-9155.
42. Hennigan A., O'Callaghan R.M., Kelly A.M. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans 2007, 35(2):424-427.
43. Barker P.A., Murphy R.A. The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins. Mol Cell Biochem 1992, 110(1):1-15.
44. Mallett S., Barclay A.N. A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today 1991, 1287:220-223.
45. Barbacid M. Nerve growth factor: a tale of 2 receptors. Oncogene 1993, 8(8):2033-2042.
46. Green S.H., Rydel R.E., Connoly J.L., Greene L.A. PC12 mutants that possess low- but not not high-affinity nerve growth factor receptors neither respond to nor internalise nerve growth factor. J Cell Biol 1986, 102(3):830-843.
47. Meakin S.O., Shooter E.M. The nerve growth factor family of receptors. Trends Neurosci 1992, 15:323-331.
48. Holtzman D.M., Kilbridge J., Li Y., Cunningham E.T., Lenn N.J., Clary D.O., et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J Neurosci 1995, 15(2):1567-1576.
49. Ehrhard P.B., Erb P., Graumann U., Otten U. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase trk in activated CD4-positive T-cell clones. Proc Natl Acad Sci USA 1993, 90:10984-10988.
50. Ehrhard P.B., Erb P., Graumann U., Schmutz B., Otten U. Expression of functional trk tyrosine kinase receptors after T cell activation. J Immunol 1994, 152(6):2705-2709.
51. Otten U., Ehrhard P., Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989, 86:10059-10063.
52. Ehrhard P.B., Ganter U., Bauer J., Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 1993, 90:5423-5427.
53. Horigome K., Pryor J.C., Bullock E.D., Johnson E.M. Mediator release from mast cells by nerve growth factor, neurotrophin specifity and receptor mediation. J Biol Chem 1993, 268(20):14881-14887.
54. Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low affinity NGF receptor. Nature 1991, 350(6320):678-683.
55. Kaplan D.R., Martin-Zanca D., Parada L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991, 350(6314):158-160.
56. Klein R., Jing S.Q., Nanduri V., O'Rourke E., Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991, 65(1):189-197.
57. Loeb D.M., Maragos J., Martin-Zanca D., Chao M.V., Parada L.F., Greene L.A. The trk proto-oncogene rescues NGF responsiveness in mutant NGF-nonresponsive PC12 cell lines. Cell 1991, 66(5):961-966.
58. Ip N.Y., Stitt T.N., Tapley P., Klein R., Glass D.J., Fandl J., et al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 1993, 10(2):137-149.
59. Lamballe F., Klein R., Barbacid M. TrkC, a new member of the trk family of tyrosin protein kinases, is a receptor for neurotrophin-3. Cell 1991, 66(5):967-979.
60. Kaplan D.R., Hempstead B.L., Martin-Zanca D., Chao M.V., Parada L.F. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991, 252(5005):554-558.
61. Barker P.A., Shooter E.M. Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTR reduces NGF binding to trkA on PC12 cells. Neuron 1994, 13(1):203-215.
62. Hantzopoulos P.A., Suri C., Glass D.J., Goldfarb M.P., Yancopoulos G.D. The low affinity NGF receptor, p75, can collaborate with each of the trks to potentiate functional responses to the neurotrophins. Neuron 1994, 13(1):187-201.
63. Mahadeo D., Kaplan L., Chao M.V., Hempstead B.L. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J Biol Chem 1994, 269(9):6884-6891.
64. Verdi J.M., Birren S.J., Ibáñez C.F., Persson H., Kaplan D.R., Benedetti M., et al. p75LNGFR regulates trk signal transduction and NGF-induced neuronal differentiation in MAH cells. Neuron 1994, 12(4):733-745.
65. Hempstead B.L., Schleifer L.S., Chao M.V. Expression of functional nerve growth factor receptors after gene transfer. Science 1989, 243(4889):373-376.
66. Barker P.A., Barbee G., Misko T.P., Shooter E.M. The low affinity receptor, p75LNTR, is palmitoylated by thioester formation through cysteine 279. J Biol Chem 1994, 269(48):30645-30650.
67. Barker P.A. p75NTR: a study in contrasts. Cell Death Differ 1998, 5(5):346-356.
68. Bibel M., Hoppe E., Barde Y.A. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 1999, 18:616-622.
69. MacPhee I.M., Barker P.A. Brain-derived neurotrophic factor binding to the p75 neurotrophin receptor reduces TrkA signalling while increasing serine phosphorylation in the TrkA intracellular domain. J Biol Chem 1997, 272(38):23547-23551.
70. Martinez-Lavin M., Solano C. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain. Medical Hypoth 2009, 72(1):64-66.
71. Lewin G.R., Ritter A.M., Mendell L.M. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 1993, 13(5):2136-2148.
72. Lewin G.R., Rueff A., Mendell L.M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994, 6:1903-1912.
73. Petty B.G., Cornblath D.R., Adornato B.T., Chaudhry V., Flexner C., Wachsman M., et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994, 36:244-246.
74. Donnerer J., Schuligoi R., Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neurosci 1992, 49(3):693-698.
75. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2):327-331.
76. Davis B.M., Albers K.M., Seroogy K.B., Katz D.M. Overexpression of nerve growth factor in transgenic mice induces novel sympathetic projections to primary sensory neurons. J Comp Neurol 1994, 349(3):464-474.
77. Lewin G.R., Mendell L.M. Nerve growth factor and nociception. Trends Neurosci 1993, 16(9):353-359.
78. Tria M.A., Fusco M., Vantini G., Mariot R. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 1994, 127(2):178-183.
79. Svensson P., Cairns B.E., Wang K., Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003, 104:241-247.
80. Davis B.M., Lewin G.R., Mendell L.M., Jones M.E., Albers K.M. Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 1993, 56(4):789-792.
81. Mamidipudi V., Wooten M.W. Dual role for p75NTR signaling in survival and cell death: can intracellular mediators provide an explanation?. J Neurosci Res 2002, 68:373-384.
82. Szeberényi J. Gene activation pathways of nerve growth factor signaling: a minireview. Neurobiology 1996, 4:1-11.
83. Wallach D., Arumugam T.U., Boldin M.P., Cantarella G., Ganesh K.A., Goltsev Y., et al. How are the regulators regulated?. The search for mechanisms that impose specificity on induction of cell death and NF-κB activation by members of the TNF/NGF receptor family. Arthritis Res 2002, 4(3):S189-S196.
84. Arai K.I., Lee F., Miyajima A., Miyatake S., Arai N., Yokata T. Cytokines: coordinators of immune and inflammatory responses. Ann Rev Biochem 1990, 59:783-836.
85. Hartung H.P., Schäfer B., Heininger K., Toyka K.V. Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes. Brain Res 1989, 489(1):113-119.
86. Gordon J.R., Galli S.J. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 1990, 346(6281):274-276.
87. Hartung H.P., Jung S., Stoll G., Zielasek J., Schmidt B., Archelos J.J., et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992, 40(2-3):197-210.
88. Lieberman A.P., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolisaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989, 86(16):6348-6352.
89. Sawada M., Kondo N., Suzumura A., Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989, 491(2):394-397.
90. Gadient R.A., Cron K.C., Otten U. Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neurosci Lett 1990, 117(3):335-340.
91. Hattori A., Tanaka E., Murase K., Ishida N., Chatani Y., Tsujimoto M., et al. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J Biol Chem 1993, 268(4):2577-2582.
92. Aloe L., Manni L., Sebastiani G., Tuveri M.A. Nerve growth factor in the synovia of patients with rheumatoid arthritis: correlation with TNF-α and IL-1β and possible functional significance. Clin Exp Rheumatol 1999, 17:632-633.
93. Manni L., Aloe L. Role of IL-1β and TNF-β in the regulation of NGF in experimentally induced arthritis in mice. Rheumatol Int 1998, 18:97-102.
94. Manni L., Lundeberg T., Fiorito S., Bonini S., Vigneti E., Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-α, interleukin-1β and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp Rheum 2003, 21:617-624.
95. Akira S., Taga T., Kishimoto T. Inerleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
96. Frei K., Malipiero U.V., Leist T.P., Zinkernagel R.M., Schwab M.E., Fontana A. On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur J Immunol 1989, 19(4):689-694.
97. Robak T., Gladalska A., Stepień H., Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Med Inflamm 1998, 7:347-353.
98. Hirohata S., Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990, 33(5):644-649.
99. Ehrhard P.B., Ganter U., Bauer J., Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 1993, 90:5423-5427.
100. Aloe L., Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977, 133(2):358-366.
101. Manning P.T., Russell J.H., Simmons B., Johnson E.M. Protection from guanethidine-induced neuronal destruction by nerve growth factor: effect of NGF on immune function. Brain Res 1985, 340(1):61-69.
102. Otten U., Ehrhard P., Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989, 86:10059-10063.
103. Thorpe L.W., Perez-Polo J.R. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J Neurosci Res 1987, 18(1):134-139.
104. Lambiase A., Bracci-Laudiero L., Bonini S., Bonini S., Starace G., D'Elios M.M., et al. Human CD4+ T cell clones produce and release nerve growth factor and express high affinity nerve growth factor receptors. J Allergy Clin Immunol 1997, 100:408-414.
105. Gee A.P., Boyle M.D., Munger K.L., Lawman M.J.P., Young M. Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA 1983, 80(23):7215-7218.
106. Otten U., Baumann J.B., Girard J. Nerve growth factor induces plasma extravasation in rat skin. Eur J Pharmacol 1984, 106(1):199-201.
107. Aloe L., Tuveri M.A., Levi-Montalcini R. Nerve growth factor and distribution of mast cells in the synovium of adult rats. Clin Exp Rheumatol 1992, 10:203-204.
108. Aloe L., Skaper S.D., Leon A., Levi-Montalcini R. Nerve growth factor and autoimmune diseases. Autoimmunity 1994, 19:141-150.
109. Shelton D.L., Zeller J., Ho W.H., Pons J., Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116(1-2):8-16.
110. Gigante A., Bevilacqua C., Pagnotta A., Manzotti S., Toesca A., Greco F. Expression of NGF. TrkA and p75 in human cartilage. Eur J Histochem 2003, 47(4):339-344.
111. Iannone F., De Bari C., Dell'Accio F., Covelli M., Patella V., Lo Bianco G., et al. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 TrkA) in human osteoarthritic chondrocytes. Rheumatology 2002, 41:1413-1418.
112. Cantarella G., Lempereur L., Presta M., Ribatti D., Lombardo G., Lazarovici P., et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB 2002, 16(10):1307-1309.
113. Emanueli C., Salis M.B., Pinna A., Graiani G., Manni L., Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimb. Circulation 2002, 106:2257-2262.
114. Turrini P., Gaetano C., Antonelli A., Capogrossi M.C., Aloe L. Nerve growth factor induces angiogenic activity in a mouse model of hindlimb ischemia. Neurosci Lett 2002, 323(2):109-112.
115. Koizumi S., Contreras M.L., Matsuda Y., Hama T. K-252a: a specific inhibitor of the action of nerve growth factor on PC12 cells. J Neurosci 1988, 8(2):715-721.
116. Raychaudhuri S.P., Sanyal M., Weltman H., Kundu-Raychaudhuri S.K. A high-affinity nerve growth factor receptor blocker improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 2004, 123(3):812-819.
117. Cattaneo A., Capsoni S., Margotti E., Righi M., Kontsekova E., Pavlik P., et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 1999, 19(22):9687-9697.
118. Owolabi J.B., Rizkalla G., Tehim A., Ross G.M., Riopelle R.J., Kamboj R., et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther 1999, 289(3):1271-1276.
119. Dostaler S.M., Ross G.M., Myers S.M., Weaver D.F., Ananthanarayanan V., Riopelle R.J. Characterization of a distinctive motif of the low molecular weight neurotrophin receptor that modulates NGF-mediated neurite outgrowth. Eur J Neurosci 1996, 8(5):870-879.
120. Lewin G.R., Rueff A., Mendell L.M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994, 6:1903-1912.
121. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2):327-331.
122. McMahon S.B., Bennett D.L.H., Priestly J.V., Shelton D.L. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by trkA-IgG fusion molecule. Nat Med 1995, 1(8):774-780.
123. Belliveau D.J., Krivko I., Kohn J., Lachance C., Pozniak C., Rusakov D., et al. NGF and Neurotrophin-3 both activate trkA on sympathetic neurons but differentially regulate survival and neuritogenesis. J Cell Biol 1997, 136(2):375-388.
124. Cordon-Cardo C., Tapley P., Jing S.Q., Nanduri V., O'Rourke E., Lamballe F., et al. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell 1991, 66(1):173-183.
125. Mischel P.S., Smith S.G., Vining E.R., Valletta J.S., Mobley W.C., Reichardt L.F. The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through trkA. J Biol Chem 2001, 276(14):11294-11301.
126. Karchewski L.A., Gratto K.A., Wetmore C., Verge V.M.K. Dynamic patterns of BDNF expression in injured sensory neurons: differential modulation by NGF and NT-3. Eur J Neurosci 2002, 16(8):1449-1462.
127. Gratto K.A., Verge V.M.K. Neurotrophin-3 down-regulates trkA mRNA, NGF high-affinity binding sites, and associated phenotype in adult DRG neurons. Eur J Neurosci 2003, 18:1535-1548.
128. Lane N.E., Schnitzer T.J., Smit M.D., Brown M.T. Efficacy and safety of PF04383119 in treating moderate to severe pain due to osteoarthritis (OA). Ann Rheum Dis 2008, 67(Suppl II):237.
129. Aloe L., Skaper S.D., Leon A., Levi-Montalcini R. Nerve growth factor and autoimmune diseases. Autoimmunity 1994, 19:141-150.
130. Aloe L., Tuveri M.A., Levi-Montalcini R. Studies on the carrageenan-induced arthritis in adult rats: presence of nerve growth factor and role of sympathetic innervation. Rheumatol Int 1992, 12:213-216.
131. Langevitz P., Buskila D., Gladman D.D. Psoriatic arthritis precipitated by physical trauma. J Rheumatol 1990, 17(5):695-697.
132. Donnerer J., Schuligoi R., Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992, 49(3):693-698.
133. Nguyen C.B., Harris L., Szönyi É, Baughman S.A., Hale V.G., Dybdal N.O., et al. Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys. Drug Metabol Dis 2000, 28(5):598-607.
134. Fox D.A. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997, 40(4):598-609.
135. Fitzgerald M. Arthritis and the nervous system. TINS 1989, 12(3):86-87.
136. Malone D.G., Wilder R.L., Saavedra-Delgado A.M.S., Metcalfe D.D. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by anti-inflammatory therapy. Arthr Rheum 1987, 30(2):130-137.
137. Zvaifler N.J. A retrospective analysis of the pathogenesis of rheumatoid arthritis. Rev Rhum 1996, 63(11):791-796.
138. Koch A.E. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998, 41(6):951-962.
139. Takei Y., Laskey R. Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol Med 2008, 14(9):381-388.
140. Aloe L., Bracci-Laudiero L., Alleva E., Lambiase A., Micera A., Tirassa P. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc Natl Acad Sci USA 1994, 25(91,22):10440-10444.
141. Baker G.H. Life events before the onset of rheumatoid arthritis. Psychother Psychosom 1982, 38(1):173-177.
142. Aloe L., Tuveri M.A., Carcassi U., Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 1992, 35(3):351-355.
143. Halliday D.A., Zettler C., Rush R.A., Scicchitano R., McNeil J.D. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 1998, 23(6):919-922.
144. Del Porto F., Aloe L., Lagana B., Triaca V., Nofroni I., D'Amelio R. Nerve growth factor and brain-derived neurothrophic factor levels in patients with rheumatic arthritis treated with TNF-alpha-blockers. Ann NY Acad Sci 2006, 1069:438-443.
145. Pozza M., Guerra M., Manzini E., Calzà L. A histochemical study of the rheumatoid synovium: focus on nitric oxide, nerve growth factor high affinity receptor, and innervation. J Rheumatol 2000, 27:1121-1127.
146. Dicou E., Masson C., Jabbour W., Nerriere V. Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients. Neuroreport 1993, 5:321-324.
147. Falcini F., Matucci Cerinic M., Lombardi A., Generini S., Pignone A., Tirassa P., et al. Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996, 55:745-748.
148. Pincelli C., Haake A.R., Benassi L., Grassilli E., Magnoni C., Ottani D., et al. Autocrine nerve growth factor protects human keratinocytes from apoptosis through its high affinity receptor (TRK): a role for BCL-2. J Invest Dermatol 1997, 109(6):757-764.
149. Gottlieb A.B., Lebwohl M., Shirin S., Sherr A., Gilleaudeau P., Singer G., et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000, 43(4):595-604.
150. Boehncke W.H., Zollner T.M., Dressel D., Kaufmann R. Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol 1997, 24(1):1-7.
151. Raychaudhuri S.P., Dutt S., Raychaudhuri S.K., Sanyal M., Farber E.M. Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br J Dermatol 2001, 144(5):931-939.
152. Langevitz P., Buskila D., Gladman D.D. Psoriatic arthritis precipitated by physical trauma. J Rheumatol 1990, 17(5):695-697.
153. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
154. Johansson O., Liang Y. Neurotrophins and their receptors in the skin: a tribute to Rita Levi-Montalcini. Biomed Rev 1999, 10:15-23.
155. Wyatt S., Shooter E.M., Davies A.M. Expression of the NGF receptor gene in sensory neurons and their cutaneous targets prior to and during innervation. Neuron 1990, 4(3):421-427.
156. Raychaudhuri S.P., Jiang W.Y., Raychaudhuri S.K. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 2008, 172(4):961-971.
157. Fantini F., Magnoni C., Bracci-Laudiero L., Pincelli C. Nerve growth factor is increased in psoriatic skin. J Invest Dermatol 1995, 105:854-855.
158. Nakamura M., Toyoda M., Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003, 149:718-730.
159. Raychaudhuri S.P., Jiang W.-Y., Farber E.M. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Dermatol Venereol 1998, 78:84-86.
160. Raychaudhuri S.P., Jiang W.-Y., Smoller B.R., Farber E.M. Nerve growth factor and its receptor system in psoriasis. Br J Dermatol 2000, 143(1):198-200.
161. White B. Immune abnormalities in systemic sclerosis. Clin Dermatol 1994, 12(3):349-359.
162. Matucci-Cerinic M., Kahaleh B.M., LeRoy E.C. The vascular involvement in systemic scelrosis. Systemic sclerosis 1995, 513-574. Lea and Febiger, Philadelphia (PA). D. Furst, P. Clements (Eds.).
163. Strehlow D., Korn J.H. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998, 10(6):572-578.
164. Hawkins R.A., Claman H.N., Clark R.A.F., Steigerwald J.C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?. Ann Inter Med 1985, 102(2):182-186.
165. Mican J.M., Metcalfe D.D. Arthritis and mast cell activation. J Allergy Clin Immunol 1990, 86:677-683.
166. Davies A.M., Bandtlow C., Heumann R., Korsching S., Rohrer H., Thoenen H. Timing and site of nerve growth factor synthesis in developing skin in relation to innervation and expression of the receptor. Nature 1987, 326(6111):353-358.
167. Pearce F.L., Thompson H.L. Some characteristics of histamine secretion from rat peritoneal mast cells stimulated with nerve growth factor. J Physiol 1986, 372:379-393.
168. Leon A., Buriani A., Dal Toso R., Fabris M., Romanello S., Aloe L., et al. Mast cells synthesize, store and release nerve growth factor. Proc Natl Acad Sci USA 1994, 91(9):3739-3743.
169. Tuveri M.A., Passiu G., Mathieu A., Aloe L. Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis. Clin Exp Rheumatol 1993, 11:319-322.
170. Kahaleh B.M., Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Athritis Rheum 1995, 38(1):1-4.
171. Piga M., Passiu G., Carta P., Satta L., Cherchi V., Pala R., et al. Increased pulmonary epithelial permeability in systemic sclerosis is associated with enhanced cutaneous nerve growth factor expression. Eur J Int Med 2000, 11:156-160.
172. Matucci-Cerinic M., Giacomelli R., Pignone A., Cagnoni M.L., Generini S., Casale R., et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis 2001, 60:487-494.
173. Bracci-Laudiero L., Aloe L., Levi-Montalcini R., Galeazzi M., Schilter D., Scully J.L., et al. Increased levels of NGF in sera of systemic lupus erythematosus patients. Neuroreport 1993, 4:563-565.
174. Xu Z., Chen Y. Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance. J Huazhong Univ Sci Technolog Med Sci 2005, 25(3):360-361.
175. Aalto K., Korhonen L., Lahdenne P., Pelkonen P., Lindholm D. Nerve growth factor in serum of children with systemic lupus erythematosus is correlated with disease activity. Cytokine 2002, 20(3):136-139.
176. Lin C.Y., Lin C.C., Hwang B., Chiang B.N. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr 1993, 152(4):309-312.
177. Santambrogio L., Benedetti M., Chao M.V., Muzaffar R., Kulig K., Gabellini N., et al. Nerve growth factor production by lymphocytes. J Immunol 1994, 153:4488-4495.
178. Falcini F., Matucci Cerinic M., Ermini M., Generini S., Lombardi A., Pignone A., et al. Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol 1996, 23:1798-1802.
179. Yamamoto M., Ito Y., Mitsuma N., Li M., Hattori N., Sobue G. Pathology-related differential expression regulation of NGF. GDNF, CNTF, and IL-6 mRNAs in human vasculitic neuropathy. Muscle Nerve 2001, 24:830-833.
180. Mitsuma N., Yamamoto M., Jijima M., Hattori N., Ito Y., Tanka F., et al. Wide range of lineages of cells expressing nerve growth factor mRNA in the nerve lesions of patients with vasculitic neuropathy: an implication of endoneurial macrophage for nerve regeneration. Neuroscience 2004, 129(1):109-117.
181. Edvinsson L., Ekman R., Jansen I., Ottosson A., Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 1987, 21(5):431-437.
182. Jansen I., Uddman R., Hocherman M., Ekman R., Jensen K., Olesen J., et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol 1986, 20(4):496-501.
183. Jansen I., Uddman R., Ekman R., Olesen J., Ottosson A., Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides 1992, 13(3):527-536.
184. Uddman R., Edvinsson L., Jansen I., Stiernholm P., Jensen K., Olesen J., et al. Peptide-containing nerve fibers in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain?. Pain 1986, 27(3):391-399.
185. Edvinsson L., Goadsby P.J. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 1995, 15(4):272-276.
186. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33(1):48-56.
187. Moskowitz M.A. The neurobiology of vascular head pain. Ann Neurol 1984, 16(2):157-168.
188. Anand P., Parrett A., Chadwick L., Hamlyn P. Nerve growth factor concentrations in human cerebral blood vessels. Neurol Neurosurg Psychiatry 1997, 62(2):199-200.
189. Tuttle J.B., Etheridge R., Creedon D.J. Receptor-mediated stimulation and inhibition of nerve growth factor secretion by vascular smooth muscle. Exp Cell Res 1993, 208(2):350-361.
190. DiStefano P.S., Friedman B., Radziejewski C., Alexander C., Boland P., Schik C.M., et al. The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 1992, 8(5):983-993.
191. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2):327-331.
192. Saldanha G., Hongo J., Plant G., Acheson J., Levy I., Anand P. Decreased CGRP, but preserved TrkA immunoreactivity in nerve fibres in inflamed human superficial temporal arteries. J Neurol Neurosurg Psychiatry 1999, 66:390-392.
193. Siminoski K., Murphy R.A., Rennert P., Heinrich G. Cortisone, testosterone, and aldosterone reduce levels of nerve growth factor messenger ribonucleic acid in L-929 fibroblasts. Endocrinology 1987, 121(4):1432-1437.
194. Jockers-Scherübl M.C., Zouboulis C.C., Boegner F., Hellweg R. Is nerve growth factor a serum marker for neurological and psychiatric complications in Behçet's disease?. Lancet 1996, 347:982.
195. Accorinti M., Bruscolini A., Lambiase A., Speranza S., Bonini S., Pivetti-Pezzi P. Nerve growth factor in Behçet's disease. Adv Exp Med Biol 2003, 528:283-285.
196. Müller W., Lautenschläger J. Generalized tendomypathy Il: phatogenesis and therapy. Z Rheumatol 1990, 49:22-29.
197. Seidel M.F., Weinreich G.F., Stratz T., Müller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007, 27(11):1025-1030.
198. Giovengo S.L., Russell I.J., Larson A.A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564-1569.
199. Lautenschläger J., Seglias J., Bruckle W., Müller W. Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol 1991, 10:168-173.
200. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37(11):1593-1601.
201. Sarcielli P., Mancini M.L., Floridi A., Coppola F., Rossi C., Nardi K., et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, 8(9):737-745.
202. Jackson H.C., Winkelmann R.K., Bickel W.H. Nerve endings in the human lumbar spinal column and related structures. J Bone Joint Surg 1966, 48(7):1272-1281.
203. Malinsky J. The ontogenetic development of nerve terminals in the intervertebral disc of man. Acta Anat 1959, 38:96-113.
204. Yoshizawa H., O'Brien J.P., Smith W.T., Trumper M. The neuropathology of intervertebral discs removed for low-back pain. J Pathol 1980, 132(2):95-104.
205. Freemont A.J., Peacock T.E., Goupille P., Hoyland J.A., O'Brien J., Jayson M.I.V. Nerve ingrowth into the diseased intervertebral disc in chronic back pain. Lancet 1997, 350(9072):178-181.
206. Freemont A.J., Watkins A., Le Maitre C., Baird P., Jeziorska M., Knight M.T.N., et al. Nerve growth factor expression and innervation of the painful intervertebral disc. J Pathol 2002, 197:286-292.
207. Seidel MF, März P, Seidel A, Storch M, Späth M, Otten U, et al. Nerve growth factor is increased in the cerebrospinal fluid of patients with spinal nerve compression. Ann Rheum Dis 297;62(1):297.
208. Iannone F., Lapadula G. The pathophysiology of osteoarthritis. Aging Clin Exp Res 2003, 15:364-372.
209. Kikuchi T., Sakuta T., Yamaguchi T. Intra-articular injection of collagenase induces experimental osteoarthritis in mature rabbits. Osteoarthritis Cartilage 1998, 6(3):177-186.
210. van de Loo F.A., Joosten L.A., van Lent P.L., Arntz O.J., van den Berg W.B. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995, 38(2):164-172.
211. Dicou E., Hurez D., Nerrière V. Natural autoantibodies against nerve growth factor in autoimmune diseases. J Neuroimmunol 1993, 47:159-167.
212. Dicou E., Perrot S., Menkes C.J., Masson C., Nerrière V. Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies. Autoimmunity 1996, 24:1-9.
213. Oppenheim R.W. Cell death during development of the nervous system. Ann Rev Neurosci 1991, 14:453-501.
214. Cruwys S.C., Garrett N.E., Kidd B.L. Sensory denervation with capsaicin attenuates inflammation and nociception in arthritic rats. Neurosci Lett 1995, 193(3):205-207.
215. Yamaguchi J., Aihara M., Kobayashi Y., Kambara T., Ikezawa Z. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci 2009, 53(1):48-54.
216. Schulte-Herbrüggen O., Fölster-Holst R., von Elstermann M., Augustin M., Hellweg R. Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis. Int Arch Allergy Immunol 2007, 144(3):211-216.
217. Mousa S.A., Cheppudira B.P., Shaqura M., Fischer O., Hofmann J., Hellweg R., et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain 2007, 130(2):502-513.
218. Lambiase A., Rama P., Bonini S., Caprioglio G., Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998, 338(17):1174-1180.
219. Lambiase A., Bonini S., Aloe L., Rama P., Bonini S. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol 2000, 118(10):1446-1449.
220. Aloe L. Nerve growth factor, human skin ulcers and vascularization. Our experience. Prog Brain Res 2004, 146:515-522.
221. Tan M.H., Bryars J., Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea 2006, 25(3):352-355.
222. Cellini M., Bendo E., Bravetti G., Campos E.C. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res 2006, 38:177-181.
223. Tuveri M.A., Generini S., Matucci-Cerinic M., Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet 2000, 356:1739-1740.
224. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol 2002, 50:393-413.
225. Banks B.E., Vernon C.A., Warner J.A. Nerve growth factor has anti-inflammatory activity in the rat hindpaw oedema test. Neurosci Lett 1984, 1(1):47. 41-5.
226. Villoslada P., Hauser S.L., Bartke I., Unger J., Heald N., Rosenberg D., et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000, 15(191,10):1799-1806.
227. Flügel A., Matsumuro K., Neumann H., Klinkert W.E.F., Birnbacher R., Lassmann H., et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 2000, 31(1):11-12.